Date: 2017-11-09
Type of information: Licensing agreement
Compound: IONIS-DNM2-2.5Rx (Dyn101)
Company: Dynacure (France) Ionis Pharmaceuticals (USA - CA)
Therapeutic area: Rare diseases - Genetic diseases
Type agreement: licensing
Action mechanism: antisense drug.
Disease: centronuclear myopathy (CNM)
Details:
- • On November 9, 2017, Ionis Pharmaceuticals and Dynacure announced that Dynacure has licensed IONIS-DNM2-2.5Rx (Dyn101), a generation 2.5 antisense drug targeting dynamin 2 for the treatment of centronuclear myopathy (CNM), for which Ionis earned a $5 million license fee in the form of Dynacure equity. Dynacure will now assume all development and commercialization responsibilities for the program.
=
Financial terms:
- Under its collaboration agreement with Dynacure, Ionis is eligible to receive additional cash or equity of up to more than $205 million in milestone payments. In addition, Ionis is eligible to receive royalties on future product sales of the drug under this collaboration.
Latest news:
Is general: Yes
